Market Analysis
Novo Nordisk (NVO) Shares Fall on Unexpected 2026 Sales Outlook
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.
BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
Ulta Beauty stock is falling premarket after Q4 earnings beat on revenue but missed on EPS, with fiscal 2026 guidance coming in below analyst expectations, sending shares down roughly 8%.
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.